Latest Safety News

Star Minerals has reported robust grade control drilling results at its Tumblegum South Gold Project, confirming excellent continuity and grade of gold mineralisation ahead of final mine planning.

ABx Group’s ALCORE subsidiary has reached a key environmental milestone for its hydrogen fluoride pilot plant in Tasmania, progressing construction and expanding its engineering team ahead of commissioning in late 2026.

Titomic Limited has secured a significant $1.7 million purchase order from the Netherlands’ Royal NLR, reinforcing its foothold in European aerospace and defense additive manufacturing.

Radiopharm Theranostics has initiated dosing in its Phase 1 clinical trial of RAD 402, a novel radiolabelled antibody targeting KLK3 in advanced prostate cancer. Early data from the trial’s initial dose levels are expected in the second half of 2026.

Blue Star Helium has completed Stage 1 of its Galactica Project, tying six wells into the Pinon Canyon facility and initiating spot-priced helium sales as it moves toward continuous operations and long-term contracts.

Javelin Minerals has launched a targeted drilling campaign at its Eureka Gold Project in WA, aiming to extend high-grade gold mineralisation and capitalise on a newly expanded mining lease. The company is poised for near-term production under a joint venture with MEGA Resources.

AML3D has landed a AU$2.61 million contract to produce critical submarine components for the US Navy using its advanced 3D metal printing technology, marking a significant step in its US defence expansion.

Alpha HPA Limited reports a surge in semiconductor sector demand driven by AI infrastructure expansion, with significant upgrades in Letters of Intent from key Japanese customers and ongoing capacity expansion.

Etherstack plc has secured a significant revenue uplift from a scope change in its primary UK government project, adding £1.53 million to its future earnings forecast for FY27.

Clover Corporation has reported a robust first half for FY26, with revenue climbing 17% and margins expanding significantly, underpinning a confident revenue forecast for the full year.

Amplia Therapeutics reports a remarkable 7.8% complete response rate and improved survival in its ACCENT pancreatic cancer trial, positioning narmafotinib as a promising new treatment option.

Lindian Resources has operationalised its Tipume Accommodation Camp at the Kangankunde Rare Earths Project, enabling workforce expansion and accelerating construction towards first production in late 2026.